2 completed, 1 recruiting, 1 withdrawn. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow 2-Propanol: new trials by email Literature Review of 2-Propanol trials Research Report on 2-Propanol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Propranolol Treatment for Postoperative Chylothorax Propranolol Hydrochloride, Placebo - Postoperative Chylothorax, Congenital Heart Disease | Phase 1 / Phase 2 | Recruiting | June Wu | 50 | 2025-09-09 | 2026-11-18 |
| Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Cobimetinib, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Completed | City of Hope Medical Center | 3 | 2023-04-28 | 2026-05-05 |
| Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | City of Hope Medical Center | 2022-06-25 | 2022-06-09 | |
| Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA Chloraprep, 0.9% Physiological Saline, ZuraPrep without IPA - Surgical Site Infection | Phase 1 | Completed | Zurex Pharma, Inc. | 208 | 2014-07-01 | 2015-03-17 |
Leukemia, Myeloid, Acute (2) · Chylothorax (1) · Heart Defects, Congenital (1) · Surgical Wound Infection (1)
City of Hope Medical Center (2) · June Wu (1) · Zurex Pharma, Inc. (1)
United States (4)
Brian Ball (1) · Guido Marcucci (1) · June Wu, MD (1) · Maggie Butler, PhD (1)
P30CA033572 (2)